SAB Biotherapeutics Inc Ordinary Shares SABS 深 滬
等待開盤 05-22 09:30:00 美东时间
3.81
+0.130
+3.53%
華盛通- 最 高3.82
- 今 開3.65
- 成交量 36.93万股
- 最 低 3.5902
- 昨 收 3.68
- 總市值 2.91亿
- 52周最高 6.60
- 市盈率 靜 --
- 換手率 0.48%
- 52周最低 1.60
- 委 比 40.33%
- 總股本 7646.41万
- 歷史最高 129.00
- 量 比 0.53
- 振 幅 6.24%
- 歷史最低 1.00
- 每 手 1
- 風險率 0.87%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | Cava、CrowdStrike、Keysight获多家大行上调目标价；家得宝绩后遭多家大行下调目标价
今日重点评级关注：Oppenheimer：维持Protara Therapeutics"跑赢大市"评级，目标价从25美元升至28美元；Piper Sandler：维持Bright Minds Biosciences"超配"评级，目标价从190美元升至220美元
05-21 12:05
Jefferies Initiates Coverage On SAB Biotherapeutics with Buy Rating, Announces Price Target of $11
Jefferies analyst Roger Song initiates coverage on SAB Biotherapeutics (NASDAQ:SABS) with a Buy rating and announces Price Target of $11.
05-20 20:34
美股大行评级 | 富国银行上调英伟达目标价从265美元升至315美元；Alamar、AEVEX获多家大行首予“买入”评级
今日重点评级关注：Needham：维持Artiva Biotherapeutics"买入"评级，目标价从18美元升至41美元；HC Wainwright & Co.：维持SAB Biotherapeutics"买入"评级，目标价从7美元升至10美元
05-13 11:46
Full Transcript: SAB Biotherapeutics Q1 2026 Earnings Call
SAB Biotherapeutics (NASDAQ:SABS) reported first-quarter financial results on T...
05-12 20:59
SAB Biotherapeutics Q1 EPS $(0.35) Misses $(0.20) Estimate.
SAB Biotherapeutics (NASDAQ:SABS) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.20) by 75 percent. This is a 37.5 percent increase over losses of $(0.56) per share from
05-12 19:48
Earnings Scheduled For May 12, 2026
Companies Reporting Before The Bell • Sionna Therapeutics (NASDAQ:SION) is proj...
05-12 19:11
美股大行评级 | Arxis、Madison Air获多家大行首予买入评价！潜在涨幅441.87%！Caribou Biosciences获HC Wainwright & Co.升目标价至11美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从9美元升至11美元；康托·菲茨杰拉德：维持Artiva Biotherapeutics"超配"评级，目标价从10美元升至40美元
05-12 12:36
Rodman & Renshaw Reiterates Buy on SAB Biotherapeutics, Maintains $13 Price Target
Rodman & Renshaw analyst Seema Sheoran reiterates SAB Biotherapeutics (NASDAQ:SABS) with a Buy and maintains $13 price target.
05-11 17:35
Emergent BioSolutions Signs Multi-Year, ~$50M Agreement With SAB Biotherapeutics For Development And Manufacturing Of SAB-142, SAB's Lead Program In Clinical Development For Autoimmune Type 1 Diabetes
The executed agreement is valued at approximately $50 million, of which $36 million is contingent on future regulatory approval and downstream milestones.Under the terms of the agreement, Emergent will provide end-to-end
04-29 19:38
SAB Biotherapeutics To Present Oral Presentation, Multiple Poster Presentations At 21st Immunology of Diabetes Society Congress On Its SAB-142 Program
SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced
04-15 20:02
